Periodic syndromes

1. High-Yield Summary

• Core Definition: Periodic syndromes (systemic autoinflammatory diseases) are monogenic or polygenic inborn errors of the innate immune system characterized by recurrent, unprovoked, self-limiting episodes of systemic inflammation, high-spiking fevers, serositis, and severe musculoskeletal manifestations (sterile acute monoarthritis, oligoarthritis, periostitis, and myalgia).
• The Orthopaedic Masquerader: Acute autoinflammatory attacks mimic bacterial septic arthritis or acute osteomyelitis. Patients present with acute joint effusion, severe antalgic guarding, fever, and marked systemic leukocytosis, with synovial fluid white blood cell (WBC) counts frequently exceeding 50,000 to 100,000 cells/μL (neutrophil-predominant). Arthrocentesis reveals negative Gram stain, sterile cultures, and absence of polarizing crystals.
• Primary Clinical Entities: The major classical hereditary periodic syndromes include Familial Mediterranean Fever (FMF; MEFV gene), Cryopyrin-Associated Periodic Syndromes (CAPS; NLRP3 gene, encompassing FCAS, MWS, and NOMID/CINCA), Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS; TNFRSF1A gene), Mevalonate Kinase Deficiency / Hyper-IgD Syndrome (MKD/HIDS; MVK gene), and the adult-onset clonal autoinflammatory disorder VEXAS syndrome (UBA1 somatic mutation).
• Catastrophic Long-Term Risk: Secondary systemic AA amyloidosis caused by persistent subclinical elevation of Serum Amyloid A (SAA). Uncontrolled chronic inflammation leads to irreversible renal glomerular amyloid deposition, nephrotic syndrome, and end-stage renal disease (ESRD), traditionally affecting up to 30% to 60% of untreated FMF and TRAPS patients.
• Management Mandate: Lifelong prophylactic colchicine is mandatory for FMF to suppress attacks and completely prevent AA amyloidosis. Targeted interleukin-1 (IL-1) receptor antagonists (anakinra, canakinumab) provide dramatic disease control for CAPS, TRAPS, MKD, and colchicine-resistant FMF. Repeated surgical arthrotomies or joint washouts are strictly contraindicated once sterile autoinflammation is confirmed.

2. Anatomy

The musculoskeletal manifestations of periodic fever syndromes involve specific anatomical structures across synovial joints, surrounding soft tissues, entheses, and developing growth plates:

Articular & Synovial Anatomy

The primary musculoskeletal target is the vascularized synovial lining of large weight-bearing diarthrodial joints. The knee joint is the single most commonly involved articulation (exceeding 50% to 60% of acute monoarticular attacks in FMF and CAPS), followed by the hip, ankle, and midtarsal joints. The synovial membrane undergoes intense acute hypervascular congestion and rapid extravasation of polymorphonuclear neutrophils into the synovial fluid space, creating tense intra-articular effusions without the pannus-mediated cartilaginous erosions characteristic of rheumatoid arthritis.

Epiphyseal and Metaphyseal Growth Plates (NOMID / CINCA)

In Neonatal-Onset Multisystem Inflammatory Disease (NOMID/CINCA), the most severe phenotype of CAPS, unregulated IL-1β signaling disrupts endochondral ossification. Pathology localizes to the physeal and epiphyseal zones of long bones and the patella, resulting in disorganized chondrocyte proliferation, premature physeal arrest, and massive asymmetric cartilaginous and bony tumor-like masses. The patella becomes grotesquely enlarged, leading to fixed flexion contractures, genu valgum, and severe patellofemoral dislocation.

Myofascial Compartments & Internervous Planes

In TRAPS, systemic autoinflammation targets the deep muscular fascia and epimysium rather than the joint cavity alone. Inflammation tracks along myofascial planes of the torso, thigh, and gluteal compartments, presenting as migratory centrifugal myalgias with overlying erythematous cutaneous induration.

When diagnostic arthrocentesis or rare surgical exposure (such as total joint arthroplasty for secondary degenerative end-stage arthritis) is performed, standard internervous planes and anatomical safe zones must be observed:

• Knee Arthrocentesis: Superolateral or mid-patellar approach entering the suprapatellar pouch, avoiding the descending genicular artery superomedially.
• Hip Exposure (if THA indicated): Direct anterior approach (Hueter interval: tensor fasciae latae innervated by superior gluteal nerve and sartorius innervated by femoral nerve) or posterior approach (sparing the sciatic nerve located posterior to the external rotators).
• Neurovascular Danger Zones: The popliteal neurovascular bundle in knees with severe chronic flexion contractures (NOMID) lies in intimate proximity to posterior capsular adhesions and hypertrophic osteochondroid masses.

3. Pathogenesis

Periodic syndromes represent disorders of the innate immune system, fundamentally distinct from autoimmune diseases. In autoimmune disorders, pathology is driven by adaptive immunity, T-cell antigen recognition, and high-titer autoantibodies (such as rheumatoid factor, anti-CCP, or antinuclear antibodies). In contrast, autoinflammatory periodic syndromes are driven by innate immune dysregulation characterized by hyperactive pattern recognition receptors (PRRs), spontaneous inflammasome activation, and unbridled pro-inflammatory cytokine production in the complete absence of autoantibodies or pathogen exposure.

Inflammasome Dysregulation & Cytokine Cascades

• NLRP3 Inflammasome (CAPS): Pathogenic gain-of-function mutations in NLRP3 (encoding cryopyrin) lower the threshold for inflammasome oligomerization. Cryopyrin associates with ASC (apoptosis-associated speck-like protein) and pro-caspase-1. Spontaneous assembly cleaves inactive pro-caspase-1 into catalytic caspase-1, which rapidly cleaves pro-interleukin-1β (pro-IL-1β) and pro-interleukin-18 (pro-IL-18) into their bioactive, potent secreted forms.
• Pyrin and MEFV (FMF): The MEFV gene encodes pyrin, a vital regulator of the pyrin inflammasome. Normal pyrin is phosphorylated and maintained in an inactive state by 14-3-3 regulatory proteins. Pathogenic MEFV variants (most notably M694V, M680I, and V726A in exon 10) prevent 14-3-3 binding or impair inhibitory phosphorylation, causing spontaneous pyrin inflammasome assembly, caspase-1 activation, and uninhibited IL-1β secretion.
• TNFRSF1A Shedding Failure (TRAPS): Mutations in the TNFRSF1A gene disrupt the cell-surface extracellular domain of the 55-kDa TNF receptor (TNFR1). Misfolded mutant receptors fail to clear from the cell surface or are retained in the endoplasmic reticulum (ER), triggering profound intracellular ER stress, ligand-independent NF-κB transcription, and failure of receptor shedding, which normally blunts circulating TNF-alpha activity.
• Mevalonate Kinase Deficiency (MKD/HIDS): Loss-of-function mutations in MVK impair the cholesterol and isoprenoid biosynthetic pathway. Depletion of downstream geranylgeranyl pyrophosphate leads to defective prenylation of small Rho GTPases (such as RhoA), triggering pyrin inflammasome hyperactivation and excessive IL-1β release.
• UBA1 Somatic Ubiquitylation Failure (VEXAS): Somatic missense mutations in codon 41 of the X-linked UBA1 gene in hematopoietic stem cells impair the primary E1 ubiquitin-activating enzyme. This induces loss of the canonical cytoplasmic UBA1b isoform, triggering widespread protein misfolding, systemic neutrophilic inflammation, cartilage destruction, and macrocytic cytopenias in older males.

Mechanism of Sterile Joint Effusion & Secondary Amyloidosis

Bioactive IL-1β is a master activator of vascular endothelial cells, inducing immediate upregulation of selectins and cell adhesion molecules (ICAM-1, VCAM-1). This stimulates massive, rapid diapedesis of polymorphonuclear neutrophils into the synovial cavity. Neutrophils undergo sterile degranulation and release matrix metalloproteinases (MMPs), yielding a purulent-appearing joint aspirate despite zero bacterial colonization.

Concurrently, circulating IL-1β, IL-6, and TNF-alpha stimulate hepatic hepatocytes to upregulate acute-phase reactants, particularly Serum Amyloid A (SAA). In chronic or inadequately treated disease, SAA cleavage fragments aggregate into insoluble beta-pleated fibrillar sheets that deposit within renal glomeruli, splenic red pulp, hepatic sinusoids, and intestinal walls, culminating in systemic AA amyloidosis and irreversible renal failure.

4. Natural History

The clinical course of periodic syndromes is defined by recurrent paroxysms of acute inflammation punctuated by asymptomatic intercritical periods, though subclinical vascular and renal inflammation often persists between attacks:

Epidemiology & Demographics

• Familial Mediterranean Fever: High prevalence among Mediterranean and Middle Eastern ancestries (Sephardic and Mizrahi Jews, Armenians, Turks, and Levantine Arabs), where carrier frequencies can reach 1 in 5 to 1 in 7. Symptoms manifest prior to age 10 in 65% of cases and before age 20 in 90%. Males and females are affected equally.
• CAPS Spectrum: Rare worldwide orphan disease (~1 to 2 per 1,000,000 live births). Autosomal dominant inheritance or de novo postzygotic somatic mosaicism. FCAS presents with cold-induced flares within hours; MWS presents in childhood with fevers, urticaria, and sensorineural hearing loss; NOMID/CINCA manifests at birth or in early infancy.
• TRAPS: Autosomal dominant inheritance affecting diverse global populations. Attacks typically begin in early childhood (median age 3 to 4 years), though late adolescent and adult-onset presentations occur.
• MKD / HIDS: Autosomal recessive disorder, predominating in Northwestern European descent (especially Dutch and French cohorts). Symptoms begin within the first year of life.
• VEXAS Syndrome: Exclusively adult-onset, affecting males typically older than 50 years of age (median onset 67 years). Prevalent cause of previously unclassified refractory relapsing polychondritis.

Untreated Disease Progression & Prognosis

Prior to the introduction of daily prophylactic colchicine, 30% to 60% of FMF patients harboring homozygous M694V mutations developed fatal renal AA amyloidosis by the fourth decade of life. Similarly, up to 25% of untreated TRAPS and MWS patients succumb to amyloid nephropathy. In NOMID, untreated children suffer progressive neurosensory deafness, cognitive impairment from chronic aseptic meningitis, severe joint deformities, and early mortality.

With modern lifelong targeted therapy (colchicine for FMF; IL-1 inhibitors for CAPS, TRAPS, and MKD), disease flares can be suppressed, secondary amyloidosis is prevented or arrested, and normal life expectancy and functional musculoskeletal mobility are preserved.

5. Clinical Presentation

History

A meticulous clinical history is paramount. Clinicians must specifically question the patient and family regarding:

• Attack Duration & Periodicity: The duration of acute episodes is the single most valuable clinical discriminator. FMF attacks are acute and brief (12 to 72 hours). MKD attacks typically last 3 to 7 days. TRAPS attacks are prolonged, persisting for 1 to 4 weeks.
• Specific Environmental or Physiological Triggers: Exposure to cold ambient temperatures or air conditioning triggers FCAS flares within 1 to 4 hours. Childhood vaccinations, emotional stress, or minor physical trauma reliably trigger MKD and FMF flares.
• Serositis Symptoms: Inquire about acute, severe peritonitis (often leading to negative exploratory laparotomies or appendectomies in childhood), pleuritic chest pain (unilateral pleuritis), or scrotal pain (acute orchitis / tunica vaginalis inflammation in FMF).
• Cutaneous Manifestations: Erysipelas-like erythema (sharply demarcated, warm, tender plaques over the dorsal foot, ankle, or lower leg) in FMF; non-pruritic, migratory, urticarial maculopapular rash in CAPS; painful centrifugal erythematous patches overlying tender muscles in TRAPS; recurrent oral aphthous ulcers in MKD and PFAPA.
• Family History: Early-onset renal failure, unexplained dialysis, early death, or recurrent “fevers of unknown origin” in consanguineous or extended family pedigrees.

Physical Examination

The physical examination during an acute flare reveals striking local and systemic findings:

• Musculoskeletal Joint Exam: Prominent tense joint effusion, severe warmth, and painful limitation of active and passive range of motion. The joint is held in antalgic flexion. Overlying skin may show erysipelas-like erythema. In chronic FMF (5% of patients) or NOMID, assess for permanent fixed flexion contractures, muscle atrophy, and joint laxity.
• Myofascial Palpation: In TRAPS, palpation along muscle bellies reveals exquisite focal tenderness without fluctuance or compartmental hardness.
• Craniofacial and Dermatologic Exam: Periorbital edema and conjunctivitis (classic in TRAPS); sensorineural hearing loss on tuning fork examination (MWS/NOMID); tender anterior and posterior cervical lymphadenopathy (prominent in MKD and PFAPA); auricular and nasal chondritis (VEXAS).

6. Imaging and Diagnostic Studies

Diagnostic Arthrocentesis (Gold Standard Laboratory Gate)

Arthrocentesis of any acutely inflamed joint is mandatory on initial presentation to rule out septic arthritis and crystalline arthropathies:

• Synovial Fluid Cytology: Grossly turbid or yellow-white purulent fluid. Synovial WBC count ranges from 25,000 to over 100,000 cells/μL, with >85% polymorphonuclear leukocytes, overlapping the classical thresholds for septic arthritis.
• Microbiology & Polarized Microscopy: Gram stain is negative for bacteria. Aerobic, anaerobic, fungal, and mycobacterial cultures remain strictly sterile. Polarizing microscopy demonstrates absence of monosodium urate or calcium pyrophosphate crystals.
• Synovial Biomarkers: Markedly elevated synovial calprotectin and IL-1β; synovial glucose is generally normal or mildly decreased (unlike severe hypoglycorrhachia in bacterial sepsis).

Radiographic Imaging Hierarchy

• Plain Radiographs:
  • Acute Phase: Soft-tissue capsular distention and joint effusion without cortical erosion or periosteal reaction.
  • Chronic / Protracted FMF Arthritis: Periarticular osteopenia; in rare aggressive forms (5%), progressive concentric joint space narrowing, subchondral sclerosis, and secondary degenerative changes of the hip joint mimicking avascular necrosis or ankylosing spondylitis.
  • NOMID / CINCA: Pathognomonic radiographic triad of patellar overgrowth (grossly enlarged, multicentric patella), irregular radiopaque epiphyseal and metaphyseal calcifications, and epiphyseal blooming with flared metaphyses.
• Magnetic Resonance Imaging (MRI): High sensitivity for delineating soft-tissue inflammation. T1-weighted images show joint effusion with low signal; T2 and STIR images reveal intense hyperintensity throughout the synovium, periarticular soft tissues, and adjacent muscle compartments. In TRAPS, MRI demonstrates superficial and deep muscular fasciitis with fluid tracking along fascial planes without focal intramuscular abscess formation.
• Point-of-Care Ultrasound (POCUS): Rapidly confirms intra-articular synovial effusion, power Doppler synovial hypervascularity, and rules out subperiosteal abscess in pediatric extremities.

Systemic Biomarkers & Molecular Genetic Confirmation

• Acute-Phase Reactants: Striking elevations in C-reactive protein (CRP > 100 mg/L), erythrocyte sedimentation rate (ESR > 60 mm/hr), and leukocytosis (15,000–30,000/μL) during attacks. Normalization between attacks confirms the episodic nature, though persistent elevation warns of ongoing subclinical inflammation.
• Serum Amyloid A (SAA): The gold-standard serum biomarker for monitoring subclinical inflammation and evaluating the risk of renal amyloidosis. Target levels during quiescent periods should be < 10 mg/L.
• Urinalysis: Routine dipstick and quantitative protein-to-creatinine ratio (spot urine protein/Cr) every 6 months to detect early proteinuria indicating renal AA amyloidosis.
• Targeted Next-Generation Sequencing (NGS) Gene Panels: Confirms diagnosis by sequencing MEFV, NLRP3, TNFRSF1A, MVK, NLRP12, and UBA1. Demonstrating homozygous or compound heterozygous pathogenic variants in MEFV confirms FMF; heterozygous pathogenic variants confirm CAPS or TRAPS.

7. Classification

Modern classification of periodic fever syndromes utilizes validated international criteria combining molecular genotype with clinical phenotype, established by the Eurofever Registry and Paediatric Rheumatology International Trials Organisation (PRINTO):

8. Treatment

Medical & Nonoperative Management

Pharmacotherapy is tailored to the specific molecular pathway underlying the disorder:

• Colchicine Prophylaxis (FMF Gold Standard):
  • Dosing: Initiated at 1.0 mg/day orally in adults (0.5 mg/day in children <5 years), titrated to a maximum of 2.0 to 2.5 mg/day until complete clinical remission and normalization of SAA/CRP are achieved.
  • Efficacy: Aborts or drastically suppresses attacks in >90% of patients and completely prevents secondary AA amyloidosis in adherent individuals. Lifelong daily therapy is mandatory regardless of attack frequency.
  • Colchicine Resistance: Defined as having ≥1 attack per month despite receiving the maximum tolerated dose for at least 6 months. Colchicine-resistant or intolerant patients are escalated to IL-1 inhibitors.
• Targeted Interleukin-1 (IL-1) Blockade:
  • Anakinra: Recombinant human IL-1 receptor antagonist (100 mg/day subcutaneous injection in adults; 1–2 mg/kg/day in children). Rapid onset within hours; ideal for acute flare control and initial diagnostic stabilization.
  • Canakinumab: Fully human monoclonal antibody selectively binding IL-1β (150 mg subcutaneous injection every 4 to 8 weeks in patients >40 kg; 2–4 mg/kg in pediatric patients). Sustained release suppresses baseline SAA, arrests hearing loss in MWS, and prevents epiphyseal destruction in NOMID.
  • Rilonacept: Soluble IL-1 receptor fusion trap protein administered weekly; FDA-approved for FCAS and MWS.
• Systemic Corticosteroids: High-dose pulse corticosteroids provide rapid temporary relief during acute TRAPS or MKD attacks. In PFAPA, a single oral dose of prednisone (1 to 2 mg/kg) at fever onset aborts the attack within hours, serving as both diagnostic confirmation and primary symptomatic therapy. Routine long-term daily corticosteroid monotherapy should be avoided due to steroid morbidity.
• Supportive Joint Care: Cryotherapy, temporary joint splinting during acute effusions, and early protected range-of-motion physical therapy following defervescence to avoid arthrofibrosis and contractures.

Operative Indications & Surgical Contraindications

• Contraindication to Emergent Arthrotomy: Emergent joint debridement and surgical arthrotomy are strictly contraindicated once sterile autoinflammation is confirmed. Performing repeat arthroscopic or open washouts on sterile joints inflicts surgical morbidity, triggers secondary wound breakdown, and exacerbates systemic flares.
• Elective Total Joint Arthroplasty (THA / TKA):
  • Indications: End-stage secondary osteoarthrosis, avascular necrosis of the femoral head (seen in protracted FMF or steroid-treated patients), and severe destructive patellofemoral/tibiofemoral arthropathy with intractable pain and loss of independent ambulation.
  • Thresholds: Radiographic Kellgren-Lawrence Grade 4 joint destruction with fixed flexion contracture >15° or progressive limb shortening.
  • Perioperative Optimization: Uninterrupted continuation of colchicine. For patients receiving biologic IL-1 inhibitors (anakinra, canakinumab), coordinate with rheumatology: anakinra has a brief half-life (4–6 hours) and may be paused 24 hours prior to surgery and restarted postoperatively upon wound stabilization; long-acting canakinumab is scheduled so elective surgery falls at the trough of the dosing interval.
• Tonsillectomy with Adenoidectomy (PFAPA): Indicated for children with PFAPA who experience refractory, severe clockwork monthly attacks causing severe school absenteeism and parental disruption. Randomized controlled trials demonstrate complete clinical resolution or significant reduction in attack frequency in over 80% to 90% of surgically treated patients.

9. Outcome

Modern therapeutic outcomes have transformed periodic syndromes from debilitating, life-shortening diseases to fully manageable chronic conditions:

• Attack Suppression & Quality of Life: Complete clinical remission or dramatic reduction (>80% reduction in annualized attack rate) is achieved in 85% to 90% of FMF patients compliant with daily colchicine. In CAPS and TRAPS, targeted IL-1 blockade rapidly induces clinical remission, resolves disabling fatigue, and normalizes patient-reported physical health scores (PedsQL, SF-36).
• Amyloidosis Prevention & Renal Survivorship: Strict suppression of Serum Amyloid A (SAA < 10 mg/L) completely halts the genesis of AA amyloidosis. In patients with established early-stage microalbuminuria, adequate colchicine or IL-1 inhibition can induce regression of proteinuria and preserve normal glomerular filtration rate.
• Prosthetic Joint Arthroplasty Survivorship: In the rare cohort of FMF patients requiring total hip or total knee arthroplasty for secondary destructive arthritis, 10-year implant survivorship exceeds 92% to 95%. When acute systemic inflammation is controlled preoperatively, rates of aseptic loosening and periprosthetic joint infection (PJI) are comparable to standard osteoarthritic control populations.
• PFAPA Surgical Remission: Following tonsillectomy with adenoidectomy, prospective studies demonstrate immediate cessation of periodic fever episodes in 80% of children, with the remainder experiencing milder, self-limiting episodes that spontaneously resolve with age.

10. Complications

Complications associated with periodic fever syndromes span acute diagnostic missteps, chronic organ damage, and medication toxicities:

11. Pearls and Pitfalls

• The “Three-Day Monoarthritis” Rule: An acute, extremely warm, tense monoarthritis of the knee or ankle that peaks rapidly and spontaneously resolves within 48 to 72 hours, leaving the joint completely pain-free between episodes, is the hallmark presentation of FMF. Bacterial septic arthritis never spontaneously resolves within 72 hours without treatment.
• Culture-Negative Septic Arthritis Trap: Never perform repeated open surgical arthrotomies or debridements on a patient with recurrent purulent-appearing joint fluid who has negative Gram stains, sterile cultures, and normal bone radiographs. Step back and consider an autoinflammatory periodic fever syndrome.
• The SAA Quiescence Rule: Normalization of CRP and ESR during intercritical periods does not guarantee absence of chronic inflammation. Serum Amyloid A (SAA) must be measured directly; low-grade subclinical SAA elevation continues to drive amyloid fibril deposition in the kidneys.
• TRAPS Fascitis Masquerader: Migratory centrifugal muscle pain in TRAPS is caused by severe perimyositis and fasciitis. On MRI, this manifests as extensive fluid tracking along fascial boundaries that can be easily misinterpreted as necrotizing fasciitis or deep muscular abscess, tempting unwarranted surgical drainage.
• The PFAPA Steroid Test: When evaluating a pediatric patient with clockwork monthly fevers, pharyngitis, and cervical lymphadenopathy, a single oral dose of prednisone (1–2 mg/kg) will abort the fever completely within 4 to 8 hours. If the fever resolves immediately, PFAPA is strongly suspected; however, warn parents that corticosteroids may shorten the inter-attack interval.
• Beware VEXAS in Older Males: Any male over 50 years presenting with unexplained relapsing polychondritis, inflammatory arthritis, recurrent fevers, and macrocytic anemia should have peripheral blood DNA tested for somatic UBA1 mutations.

12. Controversy

Several clinical and surgical controversies surround the diagnosis and management of periodic fever syndromes:

Low-Penetrance Variants & Autosomal Dominant FMF

Historically, FMF was classified as a classic autosomal recessive disease requiring two pathogenic MEFV alleles. However, modern genetic registries have identified substantial cohorts of patients exhibiting classic FMF phenotypes who possess only a single heterozygous MEFV exon 10 variant (such as M694V or E148Q), or low-penetrance variants like R92Q in TNFRSF1A. Debate continues regarding whether these patients represent true autosomal dominant transmission, epigenetic modifications, or non-classical digenic inheritance. Current consensus recommends treating patients on the basis of clinical phenotype and response to colchicine rather than withholding therapy solely due to heterozygous genetics.

Timing of Tonsillectomy in PFAPA

While tonsillectomy with adenoidectomy (T&A) boasts randomized evidence demonstrating high cure rates (>80%) in PFAPA, controversy persists regarding patient selection. Because PFAPA is a benign, self-limiting disorder that spontaneously remits in late childhood without causing organ damage or amyloidosis, many pediatric rheumatologists favor nonoperative observation with episodic single-dose corticosteroids, reserving surgical tonsillectomy exclusively for families experiencing extreme disruption of quality of life or corticosteroid-induced attack cycle acceleration.

Perioperative Biologic Management in Major Arthroplasty

When patients with autoinflammatory syndromes undergo elective total joint arthroplasty, balancing the risk of perioperative infection against the danger of a severe systemic disease flare remains challenging. Routine discontinuation of IL-1 inhibitors (such as canakinumab) weeks prior to surgery can trigger catastrophic rebound autoinflammation, wound dehiscence, and aseptic effusion. Current practice favors continuing short-acting anakinra until the day before surgery or timing long-acting agents so that surgery occurs at the trough level, restarting biologics immediately once primary surgical wound closure is secure.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Vatandoost N, Biglari S, Ranjbarnejad T et al. Association Between Pathogenic Variants in NLRP12 and Autoinflammatory Disease: A Comprehensive Systematic Review. Int J Immunogenet. 2025. doi:10.1111/iji.70001 [Level I: Systematic Review / Meta-Analysis]
• Ozen S, Demirkaya E, Erer B et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2015-208690 [Level I: Evidence-Based Consensus Guidelines / Systematic Review]
• Gattorno M, Hofer M, Federici S et al. Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases. 2019. doi:10.1136/annrheumdis-2019-215048 [Level II: Prospective Multicenter Validation Cohort Study]
• ter Haar NM, Oswald M, Jeyaratnam J et al. Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases. 2015. doi:10.1136/annrheumdis-2015-207546 [Level II: Evidence-Based Consensus Guidelines / Systematic Review]
• Beck DB, Ferrada MA, Sikora KA et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. New England Journal of Medicine. 2020. doi:10.1056/nejmoa2026834 [Level IV: Prospective Genomic Discovery / Observational Cohort Study]
• Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. International Journal of Molecular Sciences. 2019. doi:10.3390/ijms20236008 [Level V: Seminal Mechanistic Review]

15. Master Class Pro-Tip

When evaluating an acute, hyper-inflamed monoarticular knee or hip in a patient with high-spiking fevers and synovial WBC counts exceeding 80,000 cells/μL, always obtain a thorough pedigree history and inquiry into prior self-limiting febrile episodes. If synovial Gram stains, molecular bacterial PCR assays, and crystal examinations are negative, resist the surgical reflex to perform emergent arthrotomy or repeated joint debridements. An unnecessary surgical arthrotomy on a sterile autoinflammatory joint incites profound tissue trauma, exacerbates innate cytokine cascades, and introduces true iatrogenic bacterial infection into a compromised joint. Maintain empirical parenteral antibiotic coverage only while definitive microbiological cultures incubate, concurrently initiate colchicine or targeted interleukin-1 receptor antagonism under multidisciplinary rheumatology guidance, and monitor Serum Amyloid A (SAA) alongside routine acute-phase reactants to protect against occult renal amyloidosis.

Master Class Surgical Pearl: Periodic Autoinflammatory Arthropathy